Skip to main content
NUFORMIX PLC logo

NUFORMIX PLC — Investor Relations & Filings

Ticker · NFX ISIN · GB00BYW79Y38 LEI · 2138003XG3H3I2J3BJ24 IL Professional, scientific and technical activities
Open in API
Filings indexed 279 across all filing types
Latest filing 2026-03-31 Declaration of Voting R…
Country GB United Kingdom
Listing IL NFX

About NUFORMIX PLC

https://www.nuformix.com/

Nuformix PLC is a pharmaceutical development company focused on drug repurposing to address unmet medical needs, particularly in fibrosis and oncology. The company utilizes its expertise in cocrystal technology to unlock the therapeutic potential of approved drugs. This strategy involves creating new solid forms of existing medicines to improve their physical properties and performance, aiming to develop novel treatments with potentially accelerated development timelines.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an RNS announcement titled “Total Voting Rights” under DTR 5.6.1, providing the company’s issued share capital and total voting rights following a placing. It is not an AGM material or full financial report; rather it is a voting rights notification. This matches the category Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-03-31 English
£1.0 million Placing
Share Issue/Capital Change Classification · 1% confidence The document is an announcement from Nuformix plc regarding a £1.0 million share placing (capital raise). It details the issuance of new ordinary shares, the purpose of the funds, and the admission of these shares to the London Stock Exchange. This falls under the category of capital/financing updates and share issuance. Given the specific nature of the announcement regarding a new share issue to raise capital, 'CAP' (Capital/Financing Update) is the most accurate classification.
2026-03-11 English
Confirmation of US ODD for NXP002 in IPF
Regulatory Filings Classification · 1% confidence The document is a regulatory news announcement (RNS) issued by Nuformix PLC regarding the receipt of Orphan Drug Designation from the FDA for its NXP002 programme. It does not fit into specific categories like financial reports, dividends, or board changes. As it is a general corporate announcement distributed via the London Stock Exchange's RNS service, it falls under the 'Regulatory Filings' category.
2026-03-10 English
Result of AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official announcement from Nuformix plc regarding the 'Result of Annual General Meeting'. It provides a detailed table of voting results for various resolutions (ordinary and special) passed during the meeting. This aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2026-03-03 English
Posting of Annual Report and Notice of AGM
Report Publication Announcement Classification · 1% confidence The document is a short announcement (3010 characters) from Nuformix PLC stating that the Annual Financial Report and the Notice of Annual General Meeting have been posted to shareholders and are available on the company website. Following the 'Menu vs Meal' rule, this is an announcement of the publication of reports rather than the reports themselves, making it a Report Publication Announcement (RPA).
2026-02-05 English
Annual Results for period ended 30 September 2025
Audit Report / Information Classification · 1% confidence The document is titled 'Annual Results for the period ended 30 September 2025' and contains a detailed 'Non-Executive Directors' Statement', pipeline updates, and operational reviews. While it is an announcement of results, the length and depth of the content (covering strategy, clinical trial data, and business model) indicate it is the primary annual financial reporting document rather than a brief publication notice. Therefore, it is classified as an Annual Report (10-K). FY 2025
2026-01-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.